<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140811018760N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-08-16</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effects of trans-cutaneous electrical stimulation on labor pain</public_title>
      <acronym></acronym>
      <scientific_title>The effects of trans-cutaneous electrical nerve stimulation ( Interferential current (IFC))in comparison with sham IFC on labor pain among nulliparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39488</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Pregnant women who are at the start of active phase of labor (4 cm dilatation), if appropriate, were randomly assigned random block sizes of 4 and 6 blocks with a 1: 1 ratio in The two groups will intervention and control. For the Allocation Concealment, the type of intervention received is written on a piece of paper and placed inside the opaque envelopes, the back of the file will be numbered. The envelopes will be opened according to the entry of the participants and the type of group will be specified, Blinding description: Participants in this study will be blind in which group they are ,also the investigator(data assessor)  will be blind  about the individuals in the intervention or control group. And the data analyzer will be blind about data is related to the control group, or the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>labor.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, 30 to 45 minutes of electrical stimulation were obtained using a multistimulator (X735 Novin medical engineering company) at the start of the active phase (reaching the cervical dilatation of 4 cm in high electrodes and 30 to 45 minutes late in the active phase( cervical dilatation of 8 to 10 cm) will be applied at lower electrodes with a base frequency of 4000 Hz , a beat frequency of 80 to 120 Hz and pulse duration of 50 to 60 microseconds, in addition to routine care. Intervention 2: Control group: They will be treated as a placebo group and the electrodes are similar to the intervention group and will be operated in the same phase with the intervention group, only the output of the device will be zero.  Both groups will receive routine care that includes checking vital signs of the mother and the fetus, the condition of the fetues, the status of the pouch, the need for oxytocin and medication.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In case of IPD, participant data sets could be shared

When:
Starting 6 months after publication

To whom:
Only available for people working in academic institutions in Iran

Conditions:
In case of journal or reviewers request for data set

Where to obtain:
Via email and giving documents to prove their identity

How to obtain:
Sending email and documents to prove their identity

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fariba Ghaderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation Faculty, Daneshgah Ave., Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167631444</zip>
        <telephone>+98 41 3334 5121</telephone>
        <email>ghaderif@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fariba Ghaderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation Faculty, Daneshgah Ave., Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5167631444</zip>
        <telephone>+98 41 3334 5121</telephone>
        <email>ghaderif@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primiparity
one fetus
Gestational age 37 -42
Early stage of active phase(dilation 4cm)
Cephalic presentation of fetus</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>mother heart disease
mother Diabetes
mother High blood pressure
Pre-eclampsia
HELP syndrome
Any skin problems  in where electrodes will be located
unwillingness to use electrical stimulation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>080</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Single spontaneous delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, 30 to 45 minutes of electrical stimulation were obtained using a multistimulator (X735 Novin medical engineering company) at the start of the active phase (reaching the cervical dilatation of 4 cm in high electrodes and 30 to 45 minutes late in the active phase( cervical dilatation of 8 to 10 cm) will be applied at lower electrodes with a base frequency of 4000 Hz , a beat frequency of 80 to 120 Hz and pulse duration of 50 to 60 microseconds, in addition to routine care.</i_keyword>
      <i_keyword>Control group: They will be treated as a placebo group and the electrodes are similar to the intervention group and will be operated in the same phase with the intervention group, only the output of the device will be zero.  Both groups will receive routine care that includes checking vital signs of the mother and the fetus, the condition of the fetues, the status of the pouch, the need for oxytocin and medication.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain severity. Timepoint: The pain will be evaluated in several stages in both groups; first, before interventions and care, immediately after intervention, then every hour until the second stage of delivery, and at the end one hour after the delivery. Method of measurement: It will be measured using the Visual Analog Scale (VAS).</prim_outcome>
      <prim_outcome>Duration of the active stage of labor. Timepoint: We  will measure the time from the start of the active phase (reaching dilatation to 4 cm) to the end of the active phase (dilatation reaches 8 cm). Method of measurement: The duration  will be determined  from partography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Frequency of satisfactory labor progress. Timepoint: during the active phase of labor will be determined. Method of measurement: It will be determined by examining the amount of dilatation of the cervix by vaginal examination, the fetal head descending , and the characteristics of uterine contractions by using partography.</sec_outcome>
      <sec_outcome>The frequency of using sedative medications. Timepoint: From the start of interventions to an hour after the completion of labor. Method of measurement: The amount of its using dose  will be recorded in the partography.</sec_outcome>
      <sec_outcome>Frequency of need for oxytocin injection. Timepoint: From the beginning of the interventions to the end of labor. Method of measurement: The use or non-use of oxytocin will be recorded in the form of a partograghy and, if used, the number of drops per minute will be recorded in the partography.</sec_outcome>
      <sec_outcome>1st and 5th minute Apgar Score. Timepoint: The first and fifth minutes after birth will be checked. Method of measurement: The Apgar score is obtained using the Apgar score table.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-01</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Daneshgah Ave., Rehabilitation Faculty, Tabriz, Iran Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
